ArticleMolecular medicine reports2022
Oridonin attenuates dextran sulfate sodium‑induced ulcerative colitis in mice via the Sirt1/NF‑κB/p53 pathway.
Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Rhoifolin Alleviates Ulcerative Colitis by Targeting NMNAT1 and Activating SIRT1-FOXO1 Signaling to Enhance ILC3s Effector Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oridonin ameliorates ulcerative colitis by regulating the PI3K/AKT/mTOR signaling pathway to activate autophagy.International journal of molecular medicine · 2026Article
- 8-Epi-Prostaglandin F2α as a Redox Biomarker in Inflammatory Bowel Disease.Biomedicines · 2026Article
- Anti-inflammatory effects of oridonin on anExperimental and therapeutic medicine · 2026Article
- Oridonin-Loaded PDA@Gel@GO Nanocapsules Modulate NLRP3 and Epithelial Repair in Colitis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Progress in targeting the NLRP3 signaling pathway for inflammatory bowel disease (Review).Molecular medicine reports · 2025Review
- Article
- Glaucocalyxin A alleviates ulcerative colitis by inhibiting PI3K/AKT/mTOR signaling.Scientific reports · 2025Article
- Oridonin Preserves Retinal Pigmented Epithelial Cell Tight Junctions and Ameliorates Choroidal Neovascularization.Investigative ophthalmology & visual science · 2025Article
- Mechanisms of Macrophage Polarization Regulated by Oridonin: A Review.Journal of inflammation research · 2025Review
- Potential applications and mechanisms of natural products in mucosal-related diseases.Frontiers in immunology · 2025Review
- Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review.Frontiers in pharmacology · 2024Review
- Sirtuin family in autoimmune diseases.Frontiers in immunology · 2023Review
- Epithelial NADFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a serious chronic inflammatory bowel disease. Oridonin (Ori) has anti‑inflammatory, antibacterial and antitumor activities. The current study aimed to investigate the regulatory role of Ori in UC. BALB/C mice were induced to form a model of UC using dextran sulfate sodium (DSS), after which UC mice received high‑(Ori‑H) and low‑doses of Ori (Ori‑L). Subsequently, the length of the colon was measured and hematoxylin and, eosin staining was performed to detect colonic injury. Western blot analysis was performed to detect expression level in tight junction‑associated proteins in murine colon tissue. Additionally, myeloperoxidase activity and inflammatory factor concentration were detected in colon tissue using ELISA. TUNEL and western blot assays were also performed to detect cell apoptosis, and the expression level of Sirt1/NF‑κB/p53 pathway‑related proteins was also determined using western blot analysis. The results revealed that Ori ameliorated clinical symptoms and pathological lesions in mice with DSS‑induced UC. Furthermore, Ori protected the integrity of the colonic mucosal barrier, reduced the inflammatory response and decreased oxidative stress levels in mice with DSS‑induced UC. Ori treatment also inhibited intestinal mucosal cell apoptosis. These effects may have occurred via the Sirtuin‑1/NF‑κB/p53 pathway. In conclusion, Ori treatment inhibited DSS‑induced inflammatory response, oxidative stress and intestinal mucosal apoptosis in UC mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.